Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:PRPF18-CACNB2

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: PRPF18-CACNB2
	FusionPDB ID: 69005
	FusionGDB2.0 ID: 69005
		Hgene	Tgene
	Gene symbol	PRPF18	CACNB2
	Gene ID	8559	783
	Gene name	pre-mRNA processing factor 18	calcium voltage-gated channel auxiliary subunit beta 2
	Synonyms	PRP18\|hPrp18	CAB2\|CACNLB2\|CAVB2\|MYSB
	Cytomap	10p13	10p12.33-p12.31
	Type of gene	protein-coding	protein-coding
	Description	pre-mRNA-splicing factor 18PRP18 homologPRP18 pre-mRNA processing factor 18 homologPRP18 pre-mRNA processing factor 18 homolog(PRPF18)	voltage-dependent L-type calcium channel subunit beta-2calcium channel voltage-dependent subunit beta 2calcium channel, voltage-dependent, beta 2 subunitlambert-Eaton myasthenic syndrome antigen Bmyasthenic (Lambert-Eaton) syndrome antigen B
	Modification date	20200313	20200322
	UniProtAcc	.	Q08289 Main function of 5'-partner protein: FUNCTION: The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000378572,	ENST00000467034, ENST00000377315, ENST00000377319, ENST00000377329, ENST00000396576, ENST00000282343, ENST00000324631, ENST00000352115, ENST00000377328, ENST00000377331,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	6 X 5 X 4=120	15 X 16 X 3=720
	# samples	6	16
	** MAII score	log2(6/120*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(16/720*10)=-2.16992500144231 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: PRPF18 [Title/Abstract] AND CACNB2 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: PRPF18 [Title/Abstract] AND CACNB2 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	PRPF18(13647744)-CACNB2(18439812), # samples:3
Anticipated loss of major functional domain due to fusion event.	PRPF18-CACNB2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PRPF18-CACNB2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	CACNB2	GO:0051928	positive regulation of calcium ion transport	1309651
Tgene	CACNB2	GO:0070509	calcium ion import	1309651

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:13647744/chr10:18439812)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across PRPF18 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across CACNB2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000378572

PRPF18

chr10

13647744

ENST00000324631

CACNB2

chr10

18439812

3789

523

160

2385

741

ENST00000378572

PRPF18

chr10

13647744

ENST00000377328

CACNB2

chr10

18439812

1636

523

160

1635

492

ENST00000378572

PRPF18

chr10

13647744

ENST00000352115

CACNB2

chr10

18439812

2314

523

160

2313

718

ENST00000378572

PRPF18

chr10

13647744

ENST00000282343

CACNB2

chr10

18439812

3789

523

160

2385

741

ENST00000378572

PRPF18

chr10

13647744

ENST00000377331

CACNB2

chr10

18439812

2314

523

160

2313

718

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000378572	ENST00000324631	PRPF18	chr10	13647744	+	CACNB2	chr10	18439812	+	0.000411271	0.9995888
ENST00000378572	ENST00000377328	PRPF18	chr10	13647744	+	CACNB2	chr10	18439812	+	0.002996586	0.9970034
ENST00000378572	ENST00000352115	PRPF18	chr10	13647744	+	CACNB2	chr10	18439812	+	0.002848326	0.9971517
ENST00000378572	ENST00000282343	PRPF18	chr10	13647744	+	CACNB2	chr10	18439812	+	0.000411271	0.9995888
ENST00000378572	ENST00000377331	PRPF18	chr10	13647744	+	CACNB2	chr10	18439812	+	0.002848326	0.9971517

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PRPF18-CACNB2

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
PRPF18	chr10	13647744	CACNB2	chr10	18439812	523	121	LRKIEILTPEVNKSYGKGARRKNRFK

Top

Potential FusionNeoAntigen Information of PRPF18-CACNB2 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

PRPF18-CACNB2_13647744_18439812.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B35:01	TPEVNKSY	0.9825	0.9041	7	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B35:08	TPEVNKSY	0.9747	0.8886	7	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B35:05	TPEVNKSY	0.9725	0.6348	7	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-A30:08	KSYGKGARR	0.9938	0.5217	12	21
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:01	LTPEVNKSY	0.9825	0.889	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:02	LTPEVNKSY	0.9032	0.9477	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:17	LTPEVNKSY	0.8911	0.9141	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:16	LTPEVNKSY	0.6639	0.6698	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:01	ILTPEVNKSY	0.9996	0.8915	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-A30:08	KSYGKGARRK	0.9967	0.569	12	22
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:25	ILTPEVNKSY	0.9864	0.9241	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:02	ILTPEVNKSY	0.9597	0.9375	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:05	LTPEVNKSY	0.8659	0.8973	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:31	LTPEVNKSY	0.7561	0.9076	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C15:04	LTPEVNKSY	0.5498	0.934	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C03:14	LTPEVNKSY	0.0834	0.9825	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C12:04	LTPEVNKSY	0.0692	0.9964	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C06:03	LTPEVNKSY	0.05	0.9955	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C12:12	LTPEVNKSY	0.0486	0.9361	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:07	ILTPEVNKSY	0.9991	0.6614	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:05	ILTPEVNKSY	0.8943	0.902	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:31	ILTPEVNKSY	0.8407	0.9121	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B35:77	TPEVNKSY	0.9825	0.9041	7	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B35:11	TPEVNKSY	0.9816	0.9223	7	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B35:30	TPEVNKSY	0.9771	0.7986	7	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B35:17	TPEVNKSY	0.9771	0.7986	7	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B35:24	TPEVNKSY	0.9702	0.8977	7	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B18:07	TPEVNKSY	0.807	0.9029	7	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-A30:01	KSYGKGARR	0.995	0.6833	12	21
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:27	LTPEVNKSY	0.9835	0.8803	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:33	LTPEVNKSY	0.9825	0.889	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:125	LTPEVNKSY	0.9825	0.889	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:34	LTPEVNKSY	0.9825	0.889	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:135	LTPEVNKSY	0.9791	0.8829	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:11	LTPEVNKSY	0.9618	0.8437	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:08	LTPEVNKSY	0.9589	0.8509	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B35:43	LTPEVNKSY	0.9361	0.8574	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:12	LTPEVNKSY	0.9098	0.9001	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:20	LTPEVNKSY	0.8759	0.9322	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C03:02	LTPEVNKSY	0.7069	0.967	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B57:04	LTPEVNKSY	0.6947	0.6973	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B58:06	LTPEVNKSY	0.5999	0.7487	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C15:09	LTPEVNKSY	0.5498	0.934	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C12:02	LTPEVNKSY	0.4734	0.9776	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-A25:01	LTPEVNKSY	0.3678	0.8544	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C16:04	LTPEVNKSY	0.174	0.9875	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C12:03	LTPEVNKSY	0.0974	0.9851	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C16:02	LTPEVNKSY	0.0343	0.991	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C16:01	LTPEVNKSY	0.0223	0.9798	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C02:10	LTPEVNKSY	0.0014	0.985	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-C02:02	LTPEVNKSY	0.0014	0.985	6	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:33	ILTPEVNKSY	0.9996	0.8915	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:50	ILTPEVNKSY	0.9996	0.9601	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:34	ILTPEVNKSY	0.9996	0.8915	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:125	ILTPEVNKSY	0.9996	0.8915	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:27	ILTPEVNKSY	0.9995	0.8779	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:135	ILTPEVNKSY	0.9995	0.8824	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:35	ILTPEVNKSY	0.9991	0.858	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:12	ILTPEVNKSY	0.9988	0.8532	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-A30:01	KSYGKGARRK	0.9967	0.7349	12	22
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:39	ILTPEVNKSY	0.9857	0.8201	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-B15:20	ILTPEVNKSY	0.9009	0.9332	5	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	HLA-A25:01	EILTPEVNKSY	0.9774	0.9067	4	15

Top

Potential FusionNeoAntigen Information of PRPF18-CACNB2 in HLA II

PRPF18-CACNB2_13647744_18439812.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	DRB1-1001	LRKIEILTPEVNKSY	0	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	DRB1-1001	RKIEILTPEVNKSYG	1	16
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	DRB1-1002	LRKIEILTPEVNKSY	0	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	DRB1-1002	RKIEILTPEVNKSYG	1	16
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	DRB1-1003	LRKIEILTPEVNKSY	0	15
PRPF18-CACNB2	chr10	13647744	chr10	18439812	523	DRB1-1003	RKIEILTPEVNKSYG	1	16

Top

Fusion breakpoint peptide structures of PRPF18-CACNB2

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
5736	LTPEVNKSYGKGAR	PRPF18	CACNB2	chr10	13647744	chr10	18439812	523

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PRPF18-CACNB2

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B57:03	2BVO	5736	LTPEVNKSYGKGAR	-3.01019	-4.04549
HLA-A03:01	2XPG	5736	LTPEVNKSYGKGAR	-6.28383	-7.31913
HLA-A03:01	2XPG	5736	LTPEVNKSYGKGAR	-5.59305	-5.70645
HLA-B14:02	3BVN	5736	LTPEVNKSYGKGAR	-4.73996	-4.85336
HLA-B14:02	3BVN	5736	LTPEVNKSYGKGAR	-3.09097	-4.12627
HLA-B52:01	3W39	5736	LTPEVNKSYGKGAR	-5.54594	-5.65934
HLA-B52:01	3W39	5736	LTPEVNKSYGKGAR	-3.57843	-4.61373
HLA-B18:01	4JQV	5736	LTPEVNKSYGKGAR	-5.65575	-5.76915
HLA-B18:01	4JQV	5736	LTPEVNKSYGKGAR	-3.07606	-4.11136
HLA-A11:01	4UQ2	5736	LTPEVNKSYGKGAR	-9.68638	-9.79978
HLA-A11:01	4UQ2	5736	LTPEVNKSYGKGAR	-6.73518	-7.77048
HLA-A24:02	5HGA	5736	LTPEVNKSYGKGAR	-6.73076	-6.84416
HLA-A24:02	5HGA	5736	LTPEVNKSYGKGAR	-4.20633	-5.24163
HLA-B27:05	6PYJ	5736	LTPEVNKSYGKGAR	-4.80839	-4.92179
HLA-B27:05	6PYJ	5736	LTPEVNKSYGKGAR	-4.77877	-5.81407
HLA-B27:03	6PZ5	5736	LTPEVNKSYGKGAR	-3.90263	-4.93793
HLA-B44:05	3DX8	5736	LTPEVNKSYGKGAR	-5.97396	-6.08736
HLA-B44:05	3DX8	5736	LTPEVNKSYGKGAR	-5.02247	-6.05777
HLA-A02:01	6TDR	5736	LTPEVNKSYGKGAR	-4.7023	-5.7376

Top

Vaccine Design for the FusionNeoAntigens of PRPF18-CACNB2

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
PRPF18-CACNB2	chr10	13647744	chr10	18439812	12	21	KSYGKGARR	AAGTCATATGGAAAAGGAGCCAGAAGG
PRPF18-CACNB2	chr10	13647744	chr10	18439812	12	22	KSYGKGARRK	AAGTCATATGGAAAAGGAGCCAGAAGGAAA
PRPF18-CACNB2	chr10	13647744	chr10	18439812	4	15	EILTPEVNKSY	GAGATCCTCACACCAGAAGTTAACAAGTCATAT
PRPF18-CACNB2	chr10	13647744	chr10	18439812	5	15	ILTPEVNKSY	ATCCTCACACCAGAAGTTAACAAGTCATAT
PRPF18-CACNB2	chr10	13647744	chr10	18439812	6	15	LTPEVNKSY	CTCACACCAGAAGTTAACAAGTCATAT
PRPF18-CACNB2	chr10	13647744	chr10	18439812	7	15	TPEVNKSY	ACACCAGAAGTTAACAAGTCATAT

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
PRPF18-CACNB2	chr10	13647744	chr10	18439812	0	15	LRKIEILTPEVNKSY	TTAAGGAAAATAGAGATCCTCACACCAGAAGTTAACAAGTCATAT
PRPF18-CACNB2	chr10	13647744	chr10	18439812	1	16	RKIEILTPEVNKSYG	AGGAAAATAGAGATCCTCACACCAGAAGTTAACAAGTCATATGGA

Top

Information of the samples that have these potential fusion neoantigens of PRPF18-CACNB2

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
BRCA	PRPF18-CACNB2	chr10	13647744	ENST00000378572	chr10	18439812	ENST00000282343	TCGA-C8-A12L-01A

Top

Potential target of CAR-T therapy development for PRPF18-CACNB2

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to PRPF18-CACNB2

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to PRPF18-CACNB2

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)